Home・Lista de Ações・ImmunityBio Inc

ImmunityBio Inc

Fechado

SetorSaúde

7.31 0.69

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.18

Máximo

7.48

Indicadores-chave
By Trading Economics
Rendimento	-571M -633M
Vendas	5.9M 44M
EPS	-0.08
Margem de lucro	-1,431.439
Funcionários	684
EBITDA	-569M -600M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+79.31% upside

Dividendos
By Acuity
Próximos Ganhos	2 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-293M 7.5B
Abertura anterior	6.62
Fecho anterior	7.31

Sentimento de Notícias

By Acuity

50%

156 / 340 Ranking em Healthcare

ImmunityBio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 de ago. de 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 de ago. de 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 de ago. de 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 de jul. de 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 de jul. de 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29 de jul. de 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28 de jul. de 2026, 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27 de jul. de 2026, 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24 de jul. de 2026, 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23 de jul. de 2026, 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22 de jul. de 2026, 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21 de jul. de 2026, 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20 de jul. de 2026, 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Comparação entre Pares

Variação de preço

ImmunityBio Inc Previsão

Preço-alvo

By TipRanks

79.31% parte superior

Previsão para 12 meses

Média 13 USD 79.31%

Máximo 15 USD

Mínimo 12 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para ImmunityBio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para ImmunityBio Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

156 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.